Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

Abdominal aortic aneurysm (AAA) causes∼ 170 000 deaths annually worldwide. Most
guidelines recommend asymptomatic small AAAs (30 to< 50 mm in women; 30 to< 55 mm in …

Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …

Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …

Abstract Background Lp (a)(lipoprotein [a])-lowering therapy to reduce cardiovascular
disease is under investigation in phase 3 clinical trials. High Lp (a) may be implicated in …

Abstract Background and Aims Lipoprotein (a)(Lp [a]) is an established risk factor for
atherosclerotic cardiovascular disease (ASCVD). However, data on association of Lp (a) …

Abstract Background Lipoprotein (a)[Lp (a)] is a risk factor for atherosclerotic and valvular
diseases, but its possible role in other diseases has not yet been established. We conducted …